drugset / Trial / NCT05241249
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
NaSingle-groupOpen-labelOther
Summary
The primary objective of this study is to assess the impact of bethanechol therapy on R0 resection rates. The safety objective will be assessment of the safety and tolerability of bethanechol in combination with gemcitabine and nab-paclitaxel. The exploratory objective will be to evaluate genomic biomarkers associated with parasympathetic stimulation in pancreatic cancer, and the ability to reduce tumor growth rate.
Timeline
- Start
- 2022-02-01
- Primary completion
- 2026-01
- Completion
- 2026-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bethanechol | Small molecule | 100 mg | Oral |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Background | Nab-paclitaxel | Small molecule | 125 mg/m2 | — |